182 related articles for article (PubMed ID: 28741531)
21. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
[TBL] [Abstract][Full Text] [Related]
22. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.
Johnson MH; Ross AE; Alshalalfa M; Erho N; Yousefi K; Glavaris S; Fedor H; Han M; Faraj SF; Bezerra SM; Netto G; Partin AW; Trock BJ; Davicioni E; Schaeffer EM
J Urol; 2016 Nov; 196(5):1436-1444. PubMed ID: 27238617
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and clinical application of
Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
[TBL] [Abstract][Full Text] [Related]
24. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.
Smith SC; Palanisamy N; Zuhlke KA; Johnson AM; Siddiqui J; Chinnaiyan AM; Kunju LP; Cooney KA; Tomlins SA
Am J Surg Pathol; 2014 May; 38(5):615-26. PubMed ID: 24722062
[TBL] [Abstract][Full Text] [Related]
25. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
26. Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG.
Giannareas N; Zhang Q; Yang X; Na R; Tian Y; Yang Y; Ruan X; Huang D; Yang X; Wang C; Zhang P; Manninen A; Wang L; Wei GH
Nat Commun; 2022 Nov; 13(1):7320. PubMed ID: 36443337
[TBL] [Abstract][Full Text] [Related]
27. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.
Ma C; Wang X; Dai JY; Turman C; Kraft P; Stopsack KH; Loda M; Pettersson A; Mucci LA; Stanford JL; Penney KL
Cancer Epidemiol Biomarkers Prev; 2023 Oct; 32(10):1436-1443. PubMed ID: 37555839
[TBL] [Abstract][Full Text] [Related]
28. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
29. Determination of TMPRSS2-ERG, SPOP, FOXA1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract][Full Text] [Related]
30. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.
Krstanoski Z; Vokac NK; Zagorac A; Pospihalj B; Munda M; Dzeroski S; Golouh R
BMC Urol; 2016 Jul; 16(1):35. PubMed ID: 27377958
[TBL] [Abstract][Full Text] [Related]
31. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
[TBL] [Abstract][Full Text] [Related]
32. Ethnicity and ERG frequency in prostate cancer.
Sedarsky J; Degon M; Srivastava S; Dobi A
Nat Rev Urol; 2018 Feb; 15(2):125-131. PubMed ID: 28872154
[TBL] [Abstract][Full Text] [Related]
33. TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.
Zhou F; Gao S; Han D; Han W; Chen S; Patalano S; Macoska JA; He HH; Cai C
Oncogene; 2019 May; 38(22):4397-4411. PubMed ID: 30718921
[TBL] [Abstract][Full Text] [Related]
34. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion-positive prostate cancer.
Yun JW; Lee S; Chun S; Lee KW; Kim J; Kim HS
Clin Transl Med; 2021 May; 11(5):e420. PubMed ID: 34047472
[No Abstract] [Full Text] [Related]
36. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
[TBL] [Abstract][Full Text] [Related]
37. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
38. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Geybels MS; McCloskey KD; Mills IG; Stanford JL
Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
[TBL] [Abstract][Full Text] [Related]
39. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization.
Dedigama-Arachchige P; Carskadon S; Li J; Loveless I; Alhamar M; Peabody JO; Stricker H; Chitale DA; Rogers CG; Menon M; Gupta NS; Bismar TA; Williamson SR; Palanisamy N
Mod Pathol; 2020 Sep; 33(9):1791-1801. PubMed ID: 32238875
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
